Prostate Specific Antigen News and Research

RSS

PSA screening shows low-grade prostate cancers do not progress to higher grade over time

Prostate cancer aggressiveness may be established when the tumor is formed and not alter with time, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

14 Aug 2013

Qualigen's FastPack Vitamin D Immunoassay receives FDA clearance

Qualigen, Inc., a privately owned company that provides rapid, easy to use, fully quantitative diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration for its FastPack Vitamin D Immunoassay for use on its proprietary FastPack System for the rapid determination of vitamin D status.

16 Jul 2013

Research roundup: Prevention task force PSA testing recommendations often ignored; Medicaid expansion for minorities; ER and aging population

The authors examined how the growing number of elderly Americans would affect the large and increasing part of non-catastrophic outpatient care. Using Census Bureau and nationally representative survey data, researchers quantified the number of ED visits that would occur if the demographic structure of the U.S. population changed, but everything else remained the same. "We observed that it is actually infants and young adults, not the elderly, who account for the largest number of ED visits," the authors write, and conclude: However, the data do predict increases in visit lengths and the likelihood of hospitalization.

12 Jul 2013

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10 issue of JAMA.

10 Jul 2013

Survey: 54% of men opt for prostate cancer screening test despite risks

A survey of men age 40 to 74 found that 54 percent said that they would still opt for a popular prostate cancer screening test despite recent recommendations that the test not be performed, finds a new study in American Journal of Preventive Medicine. Only 13 percent said they would choose not to be tested.

9 Jul 2013

Physical activity and low calorie food may reduce risk of aggressive prostate cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center (JCCC) have published the first study on adherence to eight World Cancer Research Fund (WCRF) lifestyle recommendations and aggressive prostate cancer that shows a significantly decreased risk of highly aggressive prostate cancer associated with closer adherence to the recommendations.

30 Jun 2013

Study: Active surveillance does not appear to be good idea for black men with prostate cancer

A Johns Hopkins study of more than 1,800 men ages 52 to 62 suggests that African-Americans diagnosed with very-low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches.

26 Jun 2013

Study examines increased use of new technologies for prostate cancer treatment

Use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy and robotic prostatectomy, has increased among men with low-risk disease, high risk of noncancer mortality, or both, a population of patients who are unlikely to benefit from these treatments, according to a study in the June 26 issue of JAMA.

26 Jun 2013

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

Many men with low-risk, localized prostate cancers can safely choose active surveillance or "watchful waiting" instead of undergoing immediate treatment and have better quality of life while reducing health care costs, according to a study by researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital.

18 Jun 2013

Study shows GreenLight laser therapy effective for BPH treatment

Data presented at the American Urological Association Annual Meeting demonstrate that treatment for Benign Prostatic Hyperplasia with GreenLight XPS laser therapy with MoXy fiber, instead of transurethral resection of the prostate, results in significantly shorter hospitalization, catheterization, and recovery times for patients, while maintaining equivalent safety and efficacy.

4 Jun 2013

UC Irvine chemists create new method to identify clinically usable markers for prostate cancer in urine

Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical Society.

23 May 2013

Tokai Pharmaceuticals raises $35.5M in Series E financing

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.

15 May 2013

New clinical practice guideline for prostate cancer screening released at 2013 AUA Annual Meeting

Men ages 55 to 69 who are considering prostate cancer screening should talk with their doctors about the benefits and harms of testing and proceed based on their personal values and preferences, according to a new clinical practice guideline released today by the American Urological Association.

5 May 2013

New risk classification system proposed for prostate cancer

US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.

29 Apr 2013

New risk classification system proposed for prostate cancer

US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.

25 Apr 2013

Personalized PSA testing using genetic variants reduces unnecessary prostate biopsies

With the help of genetics, prostate specific antigen screenings may become more accurate and reduce the number of unnecessary prostate biopsies, according to a new study from Northwestern Medicine.

25 Apr 2013

Researchers study association between obesity, future prostate cancer incidence

Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with non-obese men, and were at a greater risk for subsequently developing prostate cancer, according to researchers at Columbia University's Mailman School of Public Health.

24 Apr 2013

Loss or amplification of particular DNA regions contributes to the development of prostate cancer

A new analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer, and that patients with two of these DNA changes have a high likelihood of dying from the disease.

22 Apr 2013

Research: Gene expression signature may increase risk of tumor recurrence or spread prostate cancer

A team led by Massachusetts General Hospital researchers has identified a genetic signature that appears to reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer.

16 Apr 2013

Correcting prostate specific antigen levels for genetic variants can have significant consequences

Genetic variants have been identified which can increase serum prostate specific antigen concentrations and prostate cancer risk. A new study published in The Journal of Urology reports that correcting PSA levels for these genetic variants can have significant consequences, including avoiding unnecessary biopsies for some men and eliminating false complacency for others.

16 Apr 2013

Prostate Specific Antigen News and Research

PSA screening shows low-grade prostate cancers do not progress to higher grade over time

Qualigen's FastPack Vitamin D Immunoassay receives FDA clearance

Research roundup: Prevention task force PSA testing recommendations often ignored; Medicaid expansion for minorities; ER and aging population

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Survey: 54% of men opt for prostate cancer screening test despite risks

Physical activity and low calorie food may reduce risk of aggressive prostate cancer

Study: Active surveillance does not appear to be good idea for black men with prostate cancer

Study examines increased use of new technologies for prostate cancer treatment

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

Study shows GreenLight laser therapy effective for BPH treatment

UC Irvine chemists create new method to identify clinically usable markers for prostate cancer in urine

Tokai Pharmaceuticals raises $35.5M in Series E financing

New clinical practice guideline for prostate cancer screening released at 2013 AUA Annual Meeting

New risk classification system proposed for prostate cancer

New risk classification system proposed for prostate cancer

Personalized PSA testing using genetic variants reduces unnecessary prostate biopsies

Researchers study association between obesity, future prostate cancer incidence

Loss or amplification of particular DNA regions contributes to the development of prostate cancer

Research: Gene expression signature may increase risk of tumor recurrence or spread prostate cancer

Correcting prostate specific antigen levels for genetic variants can have significant consequences

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News